Cargando…

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer

Introduction: This study aimed to compare the efficacy and safety of docetaxel + trastuzumab + pertuzumab and docetaxel + carboplatin + trastuzumab + pertuzumab for treating HER2-positive breast cancer. Method: HER2-positive breast cancer from patients diagnosed between January 2020 and September 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Binwei, Fan, Jinjia, Liu, Fang, Wen, Yixue, Li, Jie, Gao, Feng, Zhang, Yu, Feng, Gang, Du, Xiaobo, Chen, Wenzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687954/
https://www.ncbi.nlm.nih.gov/pubmed/38031361
http://dx.doi.org/10.1177/15330338231218152
_version_ 1785152080839704576
author Lin, Binwei
Fan, Jinjia
Liu, Fang
Wen, Yixue
Li, Jie
Gao, Feng
Zhang, Yu
Feng, Gang
Du, Xiaobo
Chen, Wenzhi
author_facet Lin, Binwei
Fan, Jinjia
Liu, Fang
Wen, Yixue
Li, Jie
Gao, Feng
Zhang, Yu
Feng, Gang
Du, Xiaobo
Chen, Wenzhi
author_sort Lin, Binwei
collection PubMed
description Introduction: This study aimed to compare the efficacy and safety of docetaxel + trastuzumab + pertuzumab and docetaxel + carboplatin + trastuzumab + pertuzumab for treating HER2-positive breast cancer. Method: HER2-positive breast cancer from patients diagnosed between January 2020 and September 2022 were included in this retrospective study. Docetaxel + trastuzumab + pertuzumab or docetaxel + carboplatin + trastuzumab + pertuzumab was selected as the neoadjuvant regimen. The primary endpoint was a complete pathological remission rate. Secondary endpoints were toxicity during neoadjuvant treatment, adjustment of the neoadjuvant therapy scheme, and adjuvant medication. Result: A total of 81 patients were included in this study (38 in the docetaxel + carboplatin + trastuzumab + pertuzumab treatment group and 43 in the docetaxel + trastuzumab + pertuzumab group). The complete pathological remission rates in the docetaxel + carboplatin + trastuzumab + pertuzumab and docetaxel + trastuzumab + pertuzumab groups were 44.7% (95% confidence interval: 30.2%-60.3%) and 51.2% (95% confidence interval: 36.8%-65.4%), respectively. The incidence of grade 3 or higher toxicity in the docetaxel + carboplatin + trastuzumab + pertuzumab group was significantly higher than that in the docetaxel + trastuzumab + pertuzumab group (68.4% vs 39.5%, P = .009). Neutropenia and asthenia were the most common grade 3 or higher toxicities. The incidence of neoadjuvant scheme adjustment was significantly higher in the docetaxel + carboplatin + trastuzumab + pertuzumab group than in the docetaxel + trastuzumab + pertuzumab group (26.3% vs 7.0%, P = .039). The proportion of patients who received <6 cycles of neoadjuvant therapy was significantly higher in the docetaxel + carboplatin + trastuzumab + pertuzumab group than in the docetaxel + trastuzumab + pertuzumab group (31.6% vs 4.7%, P = .004). Patients in the docetaxel + carboplatin + trastuzumab + pertuzumab group received higher doses of granulocyte-macrophage colony-stimulating factor. Conclusion: In the neoadjuvant treatment of HER2-positive breast cancer, the docetaxel + trastuzumab + pertuzumab regimen might be more tolerated than the docetaxel + carboplatin + trastuzumab + pertuzumab regimen and did not show a lower complete pathological remission rate. However, our findings require further validation through prospective studies.
format Online
Article
Text
id pubmed-10687954
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-106879542023-11-30 Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer Lin, Binwei Fan, Jinjia Liu, Fang Wen, Yixue Li, Jie Gao, Feng Zhang, Yu Feng, Gang Du, Xiaobo Chen, Wenzhi Technol Cancer Res Treat Navigating Breast Health: From Screening to Survivorship Introduction: This study aimed to compare the efficacy and safety of docetaxel + trastuzumab + pertuzumab and docetaxel + carboplatin + trastuzumab + pertuzumab for treating HER2-positive breast cancer. Method: HER2-positive breast cancer from patients diagnosed between January 2020 and September 2022 were included in this retrospective study. Docetaxel + trastuzumab + pertuzumab or docetaxel + carboplatin + trastuzumab + pertuzumab was selected as the neoadjuvant regimen. The primary endpoint was a complete pathological remission rate. Secondary endpoints were toxicity during neoadjuvant treatment, adjustment of the neoadjuvant therapy scheme, and adjuvant medication. Result: A total of 81 patients were included in this study (38 in the docetaxel + carboplatin + trastuzumab + pertuzumab treatment group and 43 in the docetaxel + trastuzumab + pertuzumab group). The complete pathological remission rates in the docetaxel + carboplatin + trastuzumab + pertuzumab and docetaxel + trastuzumab + pertuzumab groups were 44.7% (95% confidence interval: 30.2%-60.3%) and 51.2% (95% confidence interval: 36.8%-65.4%), respectively. The incidence of grade 3 or higher toxicity in the docetaxel + carboplatin + trastuzumab + pertuzumab group was significantly higher than that in the docetaxel + trastuzumab + pertuzumab group (68.4% vs 39.5%, P = .009). Neutropenia and asthenia were the most common grade 3 or higher toxicities. The incidence of neoadjuvant scheme adjustment was significantly higher in the docetaxel + carboplatin + trastuzumab + pertuzumab group than in the docetaxel + trastuzumab + pertuzumab group (26.3% vs 7.0%, P = .039). The proportion of patients who received <6 cycles of neoadjuvant therapy was significantly higher in the docetaxel + carboplatin + trastuzumab + pertuzumab group than in the docetaxel + trastuzumab + pertuzumab group (31.6% vs 4.7%, P = .004). Patients in the docetaxel + carboplatin + trastuzumab + pertuzumab group received higher doses of granulocyte-macrophage colony-stimulating factor. Conclusion: In the neoadjuvant treatment of HER2-positive breast cancer, the docetaxel + trastuzumab + pertuzumab regimen might be more tolerated than the docetaxel + carboplatin + trastuzumab + pertuzumab regimen and did not show a lower complete pathological remission rate. However, our findings require further validation through prospective studies. SAGE Publications 2023-11-29 /pmc/articles/PMC10687954/ /pubmed/38031361 http://dx.doi.org/10.1177/15330338231218152 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Navigating Breast Health: From Screening to Survivorship
Lin, Binwei
Fan, Jinjia
Liu, Fang
Wen, Yixue
Li, Jie
Gao, Feng
Zhang, Yu
Feng, Gang
Du, Xiaobo
Chen, Wenzhi
Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
title Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
title_full Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
title_fullStr Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
title_full_unstemmed Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
title_short Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
title_sort efficacy and safety of dual anti-her2 blockade and docetaxel with or without carboplatin as neoadjuvant regimen for treatment of her2-positive breast cancer
topic Navigating Breast Health: From Screening to Survivorship
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687954/
https://www.ncbi.nlm.nih.gov/pubmed/38031361
http://dx.doi.org/10.1177/15330338231218152
work_keys_str_mv AT linbinwei efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer
AT fanjinjia efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer
AT liufang efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer
AT wenyixue efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer
AT lijie efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer
AT gaofeng efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer
AT zhangyu efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer
AT fenggang efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer
AT duxiaobo efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer
AT chenwenzhi efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer